PTC Therapeutics won a bankruptcy auction for Sangamo’s Fabry disease gene therapy program, with the deal structured around a $111 million upfront payment and additional contingent milestones tied to regulatory approvals. PTC’s bid positions the company to pursue a BLA-ready AAV therapy after Sangamo’s Chapter 11 filing. Eli Lilly also acquired a separate technology tranche from Sangamo as part of the bankruptcy process. The outcome consolidates key gene-therapy assets into later-stage portfolios and may tighten competitive dynamics as Fabry therapies approach potential regulatory decisions.